Clinical disclaimer: This article is for informational purposes only and does not constitute medical advice. Never start, stop, or change medication without clinical supervision.

Key Points

  • FLOW showed a 24% lower risk of the primary kidney and cardiovascular-death composite with semaglutide versus placebo
  • This was a kidney outcomes trial in people with type 2 diabetes and CKD, not a general obesity trial
  • Semaglutide was tested against standard of care, making the incremental benefit more significant
  • The result widens semaglutide's medical significance beyond weight and glucose
  • CKD patients often have complex polypharmacy and need clinician-led care before adding or stopping drugs

FLOW matters because it moved semaglutide into the kidney outcomes conversation. In adults with type 2 diabetes and chronic kidney disease, the risk of a primary kidney or cardiovascular-death outcome was 24% lower with semaglutide than with placebo (331 vs 410 first events; hazard ratio 0.76). [1]

That is clinically significant. It suggests semaglutide is not merely a glucose or appetite drug. In the right population, it may alter renal trajectory.

The trial design

FLOW tested once-weekly semaglutide 1.0 mg in people with type 2 diabetes and CKD, on top of standard background care. [1] CKD care is already crowded with renin-angiotensin system blockade, SGLT2 inhibition, blood-pressure targets, and mineralocorticoid receptor antagonism. New entrants need to justify themselves.

FLOW showed not only a 24% reduction in the primary composite outcome, but also lower death from any cause and lower death from cardiovascular causes. [1]

What most articles miss

FLOW was in type 2 diabetes with CKD. It was not a general obesity-kidney trial. [1] Semaglutide was tested against a standard-of-care background, not against therapeutic neglect. That makes the incremental benefit more interesting, not less.

It also does not mean every person with reduced eGFR should be started on semaglutide. Phenotype, tolerability, cost, and competing priorities still matter. The dose was 1.0 mg weekly in a kidney-outcomes setting, not necessarily the same approach used in obesity-focused treatment. [1]

What this means in practice

For patients with type 2 diabetes and CKD who also carry obesity or metabolic burden, FLOW broadens the rationale for semaglutide. The conversation can be about renal and cardiovascular protection, not merely weight or HbA1c. It also supports more integrated medication review. If semaglutide is being considered within CKD care, the clinician should think simultaneously about blood pressure, volume status, gastrointestinal tolerance, renal monitoring, and other agents already in the stack.

When to involve your clinician

If you have diabetes plus CKD and are already on multiple agents, because fluid balance, other glucose-lowering drugs, and tolerability all matter. [1,2]

Bottom line

FLOW matters because it gave semaglutide hard kidney-outcome credibility in type 2 diabetes with CKD. It widens the drug's medical significance and makes simplistic weight-loss narratives look increasingly out of date. [1]

FAQ

What did FLOW show?
FLOW showed a 24% lower risk of the primary kidney and cardiovascular-death composite with semaglutide versus placebo in type 2 diabetes with CKD. [1]
Was FLOW an obesity trial?
No. It was a kidney outcomes trial in people with type 2 diabetes and chronic kidney disease. [1]
Does FLOW mean semaglutide replaces SGLT2 inhibitors?
No. It should be viewed as part of layered, evidence-based CKD care, not a replacement for existing standards.
Why is FLOW important?
Because it demonstrated hard kidney and cardiovascular outcome benefit, not just biomarker improvement. [1]
Should patients with CKD use semaglutide without supervision?
No. CKD patients often have complex polypharmacy and need monitored, clinician-led care.

References

  1. Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. nejm.org
  2. Wegovy/Ozempic semaglutide prescribing information. FDA. 2025.
  3. American College of Cardiology. FLOW Trial Summary. 2024.